This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pitt, B. Search for Related Content PubMed PubMed Citation Articles by Pitt, B.

(Circulation. 1996;93:1618-1620.)
© 1996 American Heart Association, Inc.

Articles

Risk Stratification in Patients With Unstable Angina

`Déjà Vu All Over Again'?

Bertram Pitt, MD

From the Cardiology Division, University of Michigan Medical Center, Ann Arbor, Mich.

Correspondence to Bertram Pitt, MD, UM Medical Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109-0366.

Key Words: Editorials • risk factors • angina

	Introduction

 
Considerable progress has occurred in our understanding of the pathophysiology and therapy of unstable angina pectoris.^{1 2 3} Knowledge concerning the importance of plaque rupture and thrombosis formation has led to the use of intravenous heparin, aspirin, and exploration of new antiplatelet strategies in conjunction with antianginal therapy. Despite this increased understanding in the use of antithrombotic and antianginal therapy, the fear of subsequent infarction and death remains great. These fears have led to a strategy in clinically determined high-risk and many intermediate-risk patients of coronary angiography and revascularization after stabilization before or soon after hospital discharge.¹ Delay in performing coronary angiography for several weeks to months because of inadequate resources has been associated with a relatively high risk of ischemic events and death.⁴ While a strategy of coronary angiography and revascularization (often without prior stress testing) may reduce the risk of ischemic events and death, it is nevertheless associated with an increased risk of acute complications and restenosis as well as increased cost. New strategies such as the use of stents and/or the platelet 7E3 glycoprotein 2B3A antibody hold great promise for further benefit, with a reduction in ischemic events and restenosis, but may add to cost. While the strategy of coronary angiography, revascularization, and exploration of new but expensive antithrombotic strategies is in my opinion appropriate in patients at high or intermediate risk of recurrent ischemic events, it may not be necessary in all. One of the most important challenges in the management of patients with unstable angina is risk . . . [Full Text of this Article]

This article has been cited by other articles:

				K.M. Akkerhuis, P.A.J. Klootwijk, W. Lindeboom, V.A.W.M. Umans, S. Meij, P.-P. Kint, and M.L. Simoons Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients Eur. Heart J., November 1, 2001; 22(21): 1997 - 2006. [Abstract] [PDF]

				B. L. Norgaard, K. Andersen, M. Dellborg, P. Abrahamsson, J. Ravkilde, K. Thygesen, and for the TRIM study group Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1519 - 1527. [Abstract] [Full Text] [PDF]

				S. M. Zaacks, P. R. Liebson, J. E. Calvin, J. E. Parrillo, and L. W. Klein Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications? J. Am. Coll. Cardiol., January 1, 1999; 33(1): 107 - 118. [Abstract] [Full Text] [PDF]